Haidan Guo

发表

The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity

Ludmila V. Danilova, L. Cope, V. Velculescu, 2018, Cancer Immunology Research.

Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer

Stephen Broderick, John-William Sidhom, Valsamo Anagnostou, 2018, The New England journal of medicine.

Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer

David R. Jones, V. Velculescu, J. Taube, 2019, Clinical Cancer Research.

Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.

Oluseye K. Onajole, W. Bishai, A. Kozikowski, 2013, Journal of medicinal chemistry.

Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis

R. Chaisson, V. Saini, J. Grosset, 2018, Antimicrobial Agents and Chemotherapy.

Rv2190c, an NlpC/P60 Family Protein, Is Required for Full Virulence of Mycobacterium tuberculosis

W. Bishai, D. Geiman, N. Ammerman, 2012, PloS one.

Mycobacterial Gene cuvA Is Required for Optimal Nutrient Utilization and Virulence

E. Rubin, S. Prisic, R. Husson, 2014, Infection and Immunity.

A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis

W. Bishai, Jong-Hee Lee, S. Pokkali, 2015, Nature Medicine.

Alterations in Phospholipid Catabolism in Mycobacterium Tuberculosis LysX Mutant

W. Bishai, M. Madiraju, Dorota L. Stankowska, 2011, Front. Microbio..

Risk of tuberculosis reactivation with tofacitinib (CP-690550).

W. Bishai, K. Winglee, N. Ammerman, 2012, The Journal of infectious diseases.

Inhibitor Salicyl-AMS in Mice Studies of the Mycobactin Biosynthesis Efficacy In Vivo Pharmacokinetic and

Derek S. Tan, Justin S Cisar, L. Quadri, 2014 .

Pharmacokinetic and In Vivo Efficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice

Derek S. Tan, W. Bishai, Justin S Cisar, 2013, Antimicrobial Agents and Chemotherapy.

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

David R. Jones, K. Schuebel, M. Brock, 2021, Nature.

Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen

W. Bishai, R. O’Toole, Haidan Guo, 2013, Journal of Microbiology.

Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase.

W. Bishai, G. Lamichhane, Jie Zhou, 2017, Nature chemical biology.

The Impact of Mouse Passaging of Mycobacterium tuberculosis Strains prior to Virulence Testing in the Mouse and Guinea Pig Aerosol Models

W. Bishai, G. Lamichhane, D. Geiman, 2010, PloS one.

Indoleamides are active against drug-resistant Mycobacterium tuberculosis

Marco Pieroni, Shichun Lun, Oluseye K. Onajole, 2013, Nature Communications.

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

David R. Jones, K. Schuebel, M. Brock, 2021, Nature.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Ludmila V. Danilova, L. Cope, K. Kinzler, 2019, Journal of Immunotherapy for Cancer.

Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model

W. Bishai, Radhika Gupta, N. Ammerman, 2012, PloS one.

Aerosol Mycobacterium tuberculosis Infection Causes Rapid Loss of Diversity in Gut Microbiota

Emiley Eloe-Fadrosh, William Bishai, Shashank Gupta, 2014, PloS one.

Synthetic Lethality Reveals Mechanisms of Mycobacterium tuberculosis Resistance to β-Lactams

A. Kubler, W. Bishai, K. Winglee, 2014, mBio.

Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis.

W. Bishai, S. Franzblau, B. Wan, 2012, The Journal of antimicrobial chemotherapy.

Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.

Oluseye K. Onajole, W. Bishai, G. Vistoli, 2016, Journal of medicinal chemistry.

Neoadjuvant nivolumab in resectable non-small cell lung cancer: Extended follow-up and molecular markers of response.

V. Anagnostou, M. Hellmann, J. Chaft, 2019, Journal of Clinical Oncology.

Detection of inhibitors of phenotypically drug-tolerant Mycobacterium tuberculosis using an in vitro bactericidal screen

W. Bishai, R. O’Toole, Haidan Guo, 2013, Journal of Microbiology.

Suppressor Cell–Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis

W. Bishai, Shashank Gupta, K. Winglee, 2017, The Journal of infectious diseases.

Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach

W. Bishai, Chunhong Mao, J. Aubé, 2019, Antimicrobial Agents and Chemotherapy.

Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis

W. Bishai, D. Geiman, Scott T. Nolan, 2012, Nature Communications.

Mycobacterial Gene cuvA Is Required for Optimal Nutrient Utilization and Virulence

E. Rubin, S. Prisic, R. Husson, 2014, Infection and Immunity.